Navigation Links
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
Date:4/23/2013

NEW YORK, April 23, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (NasdaqGS: INCY) stock between April 26, 2012 and August 1, 2012 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

For more information, click here: http://zlk.9nl.com/incyte-incy/.  

According to the complaint, Incyte's reported fourth quarter 2011 and first quarter 2012 sales were artificially inflated due to a large number of advanced-stage myelofibrosis patients being prescribed the drug upon FDA approval in November 2011--patients who had been too sick to participate in the clinical trials.

On August 2, 2012, Incyte disclosed that Jakafi sales growth had been much softer during the second quarter of 2012 than investors had been led to expect. Defendants also disclosed that many of the new patients prescribed Jakafi were so sick they would not have been eligible for the Phase III trial. Defendants conceded that while prescriptions to these patients had increased sales revenues, these were not revenues that would continue for the suggested three years on average that defendants claimed, as certain patients died. In response to these disclosures, the price of Incyte stock fell from its August 1, 2012 close of $24.92 per share to close at $19.57 per share on August 2, 2012.

If you suffered a loss in Incyte you have until May 6, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/incyte-incy/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington, D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (866) 367-6510
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. ICBS, Update for Shareholders.
3. NeoStems CEO Letter to Shareholders
4. Monsanto Attempts to Lockout Socially Responsible Shareholder at Annual Meeting
5. SPO Updates Shareholders on 2012 Corporate Strategy
6. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
7. Genesis Biopharma Issues Letter To Shareholders
8. Medical Marijuana Inc. Shareholder Update - PhytoSPHERE Systems, LLC
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Issues CEO Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):